CorMedix market cap CRMD
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $420.1M
- Highest close in our data
- $1.1B
- Aug 2025
CorMedix is worth $420.1M at the close on Nov 2, 2026, at $5.39 a share.
That is down 48% over the last year and up 103% over five years.
Its highest close in our data was $1.1B in Aug 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $420.1M | $420.1M | $958.1M | −57% |
| 2025 | $987.2M | $382M | $1.1B | +98% |
| 2024 | $498.2M | $169.9M | $728.4M | +142% |
| 2023 | $206.1M | $140.8M | $248.7M | +18% |
| 2022 | $174.2M | $110.3M | $278.9M | +1% |
| 2021 | $173.3M | $173.3M | $564.9M | −27% |
| 2020 | $238.7M | $71.1M | $287.9M | +30% |
| 2019 | $183.2M | $124.1M | $220.3M | +37% |
| 2018 | $133.7M | $14.7M | $221.1M | +299% |
| 2017 | $33.5M | $20.2M | $97M | −46% |
| 2016 | $61.9M | $43.5M | $151M | −14% |
| 2015 | $71.8M | $43M | $222M | +91% |
| 2014 | $37.6M | $24.1M | $45.4M | +95% |
| 2013 | $19.2M | $6.8M | $19.2M | +141% |
| 2012 | $8M | $1.9M | $8.2M | +150% |
| 2011 | $3.2M | $3.2M | $12.8M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.
| Company | Market cap |
|---|---|
| CRMDCorMedix | $420.1M |
| ARVNArvinas | $491.7M |
| PBYIPuma Biotechnology | $525.5M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $599.8M |
| COLLCollegium Pharmaceutical | $770.9M |
| ABUSArbutus Biopharma | $791.4M |
| NATRNatures Sunshine Products | $211.5M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.3B |
| ANABAnaptysbio | $1.4B |
| Peer median | $685.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on CorMedix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.